Prevnar Pneumococcal conjugate (PCV13/15/20)
Recommended Age Range:
2, 4, 6, and 12–15 months
Common Side Effects:
Fussiness, tiredness, Irritability at injection sight
Research & Testing History:
PCV7 (2000), PCV13 (2010), PCV15/20 (2021/2023); trials show strong protection vs. pneumococcal disease.
Use History:
PCV series in use since 2000
Trial Size:
PCV13: ~18,000; PCV20: ~5,000
Years on Schedule:
PCV7: 25 yrs; PCV13: 15; PCV15/20: <5
Known Safety Concerns:
Rare febrile seizures
Ingredients:
- PCV13 (Prevnar 13): 13 pneumococcal polysaccharide conjugates, CRM197 carrier protein, aluminum phosphate, sodium chloride, succinate buffer.
- PCV15 (Vaxneuvance): 15 pneumococcal polysaccharide conjugates, CRM197 carrier protein, aluminum phosphate, sodium chloride, succinate buffer.
- PCV20 (Prevnar 20): 20 pneumococcal polysaccharide conjugates, CRM197 carrier protein, aluminum phosphate, sodium chloride, succinate buffer.